Semax and Alzheimer's: What the 2025 Amyloid Plaque Study Means

A 2025 study published in Acta Naturae reports one of the most striking signals to date for an intranasal peptide in an Alzheimer model. In APPswe/PS1dE9/Blg transgenic mice, an established model of beta-amyloid pathology, 15 doses of Semax at 50 micrograms per kilogram reduced cortical plaques by a factor of 2.8 and hippocampal plaques by a factor of 2.6 compared with untreated controls. Cognitive function improved in parallel. The effect persisted into later life, from 7.5 to 8.5 months.

The result comes from an animal study, not from a clinical trial. Even so, it shifts the plausibility picture for Semax in neurodegeneration research, especially in light of a second 2025 publication that proposes a concrete molecular mechanism: copper chelation at beta-amyloid.

Semaxcognitive

Brain-boosting nootropic peptide derived from ACTH. Increases BDNF (brain-derived neurotrophic factor), enhances focus, memory, and mental clarity. Widely used in Russian clinical practice for cognitive enhancement.

What the study showed (Radchenko 2025)

Study design

The Radchenko group at the Institute of Molecular Genetics used the APPswe/PS1dE9/Blg transgenic line. This line co-expresses two human familial Alzheimer mutations: the Swedish APP double mutation and the exon-9 deletion of presenilin-1. The model develops characteristic amyloid plaques and behavioral deficits that reproduce essential aspects of human Alzheimer pathology.

The animals received Semax at a dose of 50 micrograms per kilogram intranasally. Fifteen doses were administered on a two-day rhythm over one month. The readouts were plaque burden in cortex and hippocampus, behavioral cognition, and persistence into later age.

Results

The central numbers are unusual for a neurodegenerative intervention. Cortical amyloid plaque density fell by a factor of 2.8 compared with untreated transgenic controls. Hippocampal plaque density fell by a factor of 2.6. Both reductions were statistically robust and consistent across animals.

Behavioral cognition improved in parallel with plaque reduction. Treated mice performed better in the cognitive tests used, which matches the expected pattern when amyloid reduction translates into a functional benefit rather than remaining a purely biochemical shift. The persistence finding is as important as the acute effect: the signal remained stable at 7.5 to 8.5 months, suggesting that the one-month treatment produced a change that lasted beyond the dosing window.

Mechanism: How Semax acts

Two lines of evidence now converge on a dual mechanism for Semax in Alzheimer-adjacent biology. The first is a direct biochemical interaction with the pathological beta-amyloid species. The second is the long-established neurotrophic axis that Semax activates in the hippocampus.

Copper chelation (Tomasello 2025)

In a separate 2025 paper in Bioinorganic Chemistry and Applications (Tomasello MF et al., PMID 40496623), the authors show that Semax acts as a copper chelator. In vitro, Semax extracts Cu(II) ions from preformed Cu(II)-beta-amyloid complexes. This matters because copper binding to beta-amyloid is considered one of the drivers of redox stress, reactive oxygen species formation, and oligomer toxicity. By silencing the redox activity of these complexes, Semax would interrupt one of the most damaging downstream consequences of amyloid accumulation, even before the plaques themselves are cleared.

The chelation finding is notable because it fits the plaque data set. A peptide that removes catalytically active copper from beta-amyloid should shift the equilibrium toward clearance, lower secondary oxidative damage, and reduce plaque burden over weeks. Radchenko's in vivo observation and Tomasello's in vitro mechanism are consistent.

BDNF, NGF, and the TrkB pathway (Dolotov 2006)

Semax's neurotrophic axis is older and better documented. The foundational work by Dolotov and colleagues, published in 2006 in Brain Research (PMID 16996037), showed that intranasal Semax upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the rat hippocampus while also affecting the expression of nerve growth factor (NGF). BDNF/TrkB signaling is central to hippocampal synaptic plasticity, long-term potentiation, and memory formation.

This is the second arm of the dual mechanism. In an Alzheimer model that loses hippocampal synaptic integrity over time, a peptide that both lowers amyloid-copper toxicity and reactivates BDNF/NGF-driven plasticity has two independent mechanistic entry points. The cognitive improvement reported by Radchenko alongside plaque reduction fits this combination more cleanly than either mechanism alone.

Context: The amyloid hypothesis and other approaches

The amyloid hypothesis has dominated Alzheimer research for three decades, with mixed clinical results. Passive immunotherapy with aducanumab (Aduhelm) was approved by the FDA in 2021 under considerable controversy and was later withdrawn from the market. Lecanemab (Leqembi) received regular approval in 2023 and showed a moderate slowing of cognitive decline alongside a notable rate of amyloid-related imaging abnormalities (ARIA). Donanemab provided another data point. GLP-1 agonists, as a non-amyloid approach, were tested in 2025 in EVOKE and EVOKE+ and missed their primary endpoints.

Against this backdrop, a small Russian heptapeptide with a plaque-reduction signal in the low microgram range and no reported ARIA is unusual. The Radchenko and Tomasello findings do not overturn the amyloid hypothesis. They extend it in a direction little explored in the West: metal-mediated toxicity as a therapeutic target, combined with neurotrophic restoration.

Update June 2026: Semax goes before the FDA committee in July

Since this study appeared, the topic has also gained regulatory momentum. On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee (PCAC) of the US FDA will review seven research peptides for the so-called 503A bulks list, including Semax on the second day. The 2025 amyloid plaque data are considered one of the reasons for the revived scientific interest in the heptapeptide.

Important for context: this is a US compounding procedure for licensed pharmacies, not a drug approval, and certainly not a recognized Alzheimer indication. It changes nothing about the status in Europe: Semax remains research-use-only material here. We have laid out the details and the likely outcome of the vote in a dedicated analysis:

FDA PCAC hearing July 2026: which 7 peptides are up for clearance

In cognition research, Semax is also frequently studied together with Selank. The combined research blend is available as its own material.

Semax/Selankcognitive

Pre-mixed combination of the two leading nootropic peptides in one vial. Semax boosts focus and BDNF, Selank reduces anxiety and enhances calm. Together they provide balanced cognitive enhancement for research.

What this does NOT mean

Honest framing matters more here than enthusiasm. The 2025 Radchenko data are preclinical. They are the strongest published plaque-reduction signal for Semax so far, but they are mouse data. Several amyloid-modifying approaches have produced encouraging rodent data without successful human translation. The APPswe/PS1dE9 model reproduces some, but not all, features of human Alzheimer's disease, and clinical Alzheimer's is a process unfolding over decades that no mouse model fully reproduces.

There is no human randomized controlled trial of Semax in Alzheimer's. The Russian clinical data on Semax focus on post-stroke rehabilitation, cognitive disorders in a broader sense, and short-term cognitive performance in healthy people. An Alzheimer RCT would require at least a biomarker-supported phase-2 program, probably with PET amyloid imaging, CSF tau measurements, or plasma phospho-tau endpoints, complemented by established cognitive scales.

Implications for further research

The Radchenko and Tomasello findings define a clear research agenda. Four questions stand out.

First: can the plaque-reduction signal be replicated in independent labs, in alternative Alzheimer models (e.g., 5xFAD, 3xTg-AD), and with different dosing intervals? Replication is the weak point of most rodent neurodegeneration literature, and Semax is no exception here.

Second: does the copper-chelation mechanism carry over from the in vitro extraction of Cu(II) from Cu(II)-amyloid complexes to the intact rodent brain under in vivo redox conditions? Metal-chelation therapy has a long and mixed history in Alzheimer research, from clioquinol to PBT2, and mechanistic work remains decisive.

Third: how do the plaque and cognition signals interact with the BDNF/NGF arm? Separating the chelation contribution from the neurotrophic contribution is difficult in a model where both mechanisms operate. Combination designs or pathway-specific knockouts could resolve this.

Fourth, the intranasal route of administration deserves continued attention. Semax reaches the brain via the olfactory route and bypasses the blood-brain barrier, which is one of the old hurdles for peptide-based therapeutics in neurodegeneration. The APPswe/PS1dE9 data were generated with a practical, non-invasive protocol that is closer to a possible human study than a stereotaxic injection.

The 2025 results do not mean that Semax will work in Alzheimer patients. They mean that the research program around Semax has generated a hypothesis that can no longer be dismissed without data. For researchers interested in peptide approaches in neurodegeneration, that is a meaningful shift.

For qualified laboratories and researchers in the European Union, research-grade Semax is available for in vitro and preclinical work. It is not an Alzheimer therapy and not a clinical product. It is the same molecule that the Radchenko group dosed into their transgenic mice, supplied in the same form.

References

1. Radchenko AI, et al. Intranasal Semax in APPswe/PS1dE9/Blg transgenic mice. Acta Naturae, 2025. PMID 41479572. https://pmc.ncbi.nlm.nih.gov/articles/PMC12755871/
2. Tomasello MF, et al. Semax as a copper chelator: extraction of Cu(II) from Cu(II)-Abeta complexes. Bioinorganic Chemistry and Applications, 2025. PMID 40496623.
3. Dolotov OV, et al. Semax, an ACTH(4-10) analogue with nootropic effects, regulates BDNF and TrkB expression in the rat hippocampus. Brain Research, 2006. PMID 16996037.
4. Filippenkov IB, et al. ACTH-like peptides normalize gene expression after transient middle cerebral artery occlusion. Biomedicines, 2024. PMID 39767736.
5. Kaplan AY, et al. Semax in healthy human subjects. Neuroscience Research Communications, 1996.

Frequently Asked Questions